Evidence map›Paper›PMID 35677515›Full record

ArticleJournal of clinical and experimental hepatology

SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency Ablation.

Amr Abdel-Moety, Nahed Baddour, Perihan Salem, Hesham El-Tobgy, Assem El-Shendidi

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. The Role of N6-Methyladenosine in Mitochondrial Dysfunction and Pathology.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amr Abdel-MoetyDepartment of Internal Medicine (Hepatobiliary Unit), Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Nahed BaddourDepartment of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Perihan SalemDepartment of Internal Medicine (Hepatobiliary Unit), Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Hesham El-TobgyDepartment of Internal Medicine, Alexandria Military Hospitals, Egypt.
Assem El-ShendidiDepartment of Internal Medicine (Hepatobiliary Unit), Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Autophagy is a process that allows the degradation of detrimental components through the lysosome to maintain cellular homeostasis under variable stimuli. SQSTM1 is a key molecule involved in functional autophagy and is linked to different signaling pathways, oxidative responses, and inflammation. Dysregulation of autophagy is reported in a broad spectrum of diseases. Accumulation of SQSTM1 reflects impaired autophagy, which is related to carcinogenesis and progression of various tumors, including hepatocellular carcinoma (HCC). This study investigated SQSTM1 protein expression in HCC and its relation to the clinicopathological features and the likelihood of tumor recurrence after radiofrequency ablation (RFA). Methods: This study included 50 patients with cirrhotic HCC of Barcelona Clinic Liver Cancer stages 0/A-B eligible for RFA. Tumor and peritumor biopsies were obtained just prior to local ablation and assessed for tumor pathological grade and SQSTM1 expression by immunohistochemistry. Patients were followed for one year after achieving complete ablation to detect any tumor recurrence. Results: Serum alpha-fetoprotein level ( Conclusions: SQSTM1 expression could determine aggressive HCC, even with reasonable tumor size and number, and identify the subset of HCC patients with short overall survival and unfavorable prognosis. SQSTM1 expression could not predict post-RFA intrahepatic HCC recurrence. SQSTM1 may be a potential biomarker and target for the selection of HCC patients for future therapies.

Indexed as

AFP, Alpha fetoproteinBCLC, Barcelona Clinic Liver CancerCT, Computed tomographyCTP, Child-Turcotte-PughELISA, Enzyme-linked immunosorbent assayFNAC, Fine-needle aspiration cytologyHCC, Hepatocellular carcinomaHCV, Hepatitis C virushepatocellular carcinomaKeap1, Kelch-like ECH-associated protein 1mRECIST, modified Response Evaluation Criteria in Solid TumorsMRI, Magnetic resonance imagingmTORC1, mammalian target of rapamycin complex 1NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cellsNrf2, Nuclear factor erythroid 2-related factor 2radiofrequency ablationRFA, Radiofrequency ablationSQSTM1SQSTM/p62, Sequestosome 1/protein 62tumor recurrence

Identifiers

PMID35677515
PMCPMC9168718
OpenAlexW4200306037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.